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Abstract
In previous work, we proposed a method for detecting differential gene expression based on change-point of expression
profile. This non-parametric change-point method gave promising result in both simulation study and public dataset
experiment. However, the performance is still limited by the less sensitiveness to the right bound and the statistical
significance of the statistics has not been fully explored. To overcome the insensitiveness to the right bound we modified
the original method by adding a weight function to the Dn statistic. Simulation study showed that the weighted change-
point statistics method is significantly better than the original NPCPS in terms of ROC, false positive rate, as well as change-
point estimate. The mean absolute error of the estimated change-point by weighted change-point method was 0.03,
reduced by more than 50% comparing with the original 0.06, and the mean FPR was reduced by more than 55%.
Experiment on microarray Dataset I resulted in 3974 differentially expressed genes out of total 5293 genes; experiment on
microarray Dataset II resulted in 9983 differentially expressed genes among total 12576 genes. In summary, the method
proposed here is an effective modification to the previous method especially when only a small subset of cancer samples
has DGE.
Citation: Wang Y, Sun G, Ji Z, Xing C, Liang Y (2012) Weighted Change-Point Method for Detecting Differential Gene Expression in Breast Cancer Microarray
Data. PLoS ONE 7(1): e29860. doi:10.1371/journal.pone.0029860
Editor: Raya Khanin, Memorial Sloan Kettering Cancer Center, United States of America
Received September 5, 2011; Accepted December 5, 2011; Published January 20, 2012
Copyright:  2012 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by the National High-technology Development Project (2009AA02Z307), the National Natural Science Foundation of
China (10872077, 60703025), the Education Department of Jilin Province (2011449) of China, the Natural Science Foundation of Inner Mongolia (2011MS0907) of
China, and Research Program at Universities of Inner Mongolia Autonomous Region (NJ10320). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ycliang@jlu.edu.cn
Introduction
Selecting differentially expressed genes [1,2] is one of the most
important tasks in microarray applications. Many methods were
proposed to compare patterns of gene expression between cells or
tissues of different kinds and under different conditions, for
example, between normal and cancer cells. The goal of these
methods has been to enable faster, simpler, more sensitive and
systematic analyses [3]. Among these methods, t-statistics is a
classical and widely-used DGE detecting methods, which works on
the hypothesis that all the cancer samples are over-expressed
compared with the normal samples [4]. Several other methods are
also based on this hypothesis, such as empirical Bayes approach
[5], mixture model approach [6], and SAM [7]. However,
considering the heterogeneity of gene activation, many genes show
increased expressions in disease samples, but only for a small
number of those samples [8]. The study of Tomlins et al. [9,10]
shows that t-statistics has low power in this case, and they
introduced cancer outlier profile analysis (COPA) method which
performs better than the traditional t-statistics for cancer
microarray data sets. More recently, several progresses have been
made in this direction with the aim to design better statistics to
account for the heterogeneous activation pattern of the cancer
genes, such as non-parametric method PPST (permutation
percentile separability test) [11] (Lyons-Weiler, 2004) and LRS
(likelihood ratio test) [12] (Hu, 2008); percentile based methods
OS (outlier sum) [13] (Tibshirani, 2007), ORT (outlier robust t-
statistics) [14] (Wu, 2007) and TriORT [15] as an improvement to
ORT; MOST (maximum ordered subset t-statistics) [16] (Lian,
2008) and TriMOST [17], which is an improvement to MOST.
Previously, we proposed a non-parametric change point
statistics (NPCPS) method [18] based on modified Kolmogorov
statistic to detect the single change-point (CP) in a data sequence
[19]. This method compares directly the data distribution of
normal and cancer group to detect conveniently the existence of
possible change-point in the cancer group, giving an estimate of
the change-point as well. Besides, as a non-parametric inferential
method, NPCPS does not make assumptions about the probability
distributions of the variables being assessed, and accordingly, it is
not necessary to normalize the microarray data before calculating
the test statistic like other parametric methods usually do. By
simulation and experiment, NPCPS is effective for DGE detection
and outperforms the compared methods with better ROC results
in many circumstances [18]. However, the performance of this
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29860change-point based method is still limited by the less sensitiveness
to the right bound and the statistical significance of the static has
not been fully explored. Therefore, here we present an improved
method, Weighted Change-Point Statistics (WCPS) aiming to
break the limitations.
Results and Discussion
Monte Carlo simulation and ROC analysis
Monte Carlo simulation was applied to evaluate the hypothesis
test used in the proposed method. For each Monte Carlo
simulation, the proposed method was applied to an artificial
7000-gene dataset in normal distribution (mean=0, standard
deviation=1) and multiple simulations were carried out with
positive m=2, and different sample size n (normal group size n1
and cancer group size n2 equal to n/2) and DGE sample size k
(0,k,n2). The false positive rate (FPR, i.e. genes with DGE were
recognized as no DGE existence) and average estimate of change
point (Table 1 and Table 2) were computed. Generally, for both
methods, the estimate of change point and FPR enhanced together
when k increased; after FPR dropped below the significance level
(0.01 in this case), the estimated position converges to the actual
position. However, for a given k, the proposed method
outperforms the original NPCPS with closer CP estimate and
lower FPR; with k increasing, the proposed method converged
faster to the true change point and reached zero FPR before the
original NPCPS method. For normally distributed data, between
WCPS and NPCPS, the FPR is 0.09 versus 0.17; for skew-
normally distributed data, the FPR was 0.08 versus 0.12. Besides,
the mean absolute error (MAE) of estimated CP by WCPS was
0.03, while MAE by NPCPS was more than 0.06.
Results of more simulations with different m and k are in Table 3.
The proposed method and other seven methods as comparison
were then applied to two types of dataset, one in normal
distribution and the other in skew-normal distribution, and each
type contained several datasets with different m, n and k. The other
seven methods are NPCPS, LRS, TriMOST, TriORT, COPA,
OS and T-statistics. The AUC of ROC analysis on both types of
dataset is summarized in Table 4 and Table 5, and the ROC in
Fig. 1 and Fig. 2, respectively.
Results show that the proposed method had larger AUC than
the other methods, more significantly when k was smaller.
Generally, change-point based methods, namely WCPS, NPCPS
and LRS were better than the percentile-based methods in terms
of ROC in the simulation study, while WCPS had the best
performance; among the percentile based methods, T-statistic was
Table 1. CP estimate and FPR on data in normal distribution of size n1=n2=25 with positive m=2.
k Actual CP Average estimate of CP FPR with C(0.01)=1.628
WCPS NPCPS WCPS NPCPS
1 0.98 0.84 0.60 0.65 0.84
3 0.94 0.92 0.80 0.14 0.48
5 0.90 0.89 0.84 0.04 0.16
7 0.86 0.84 0.82 0.02 0.04
9 0.82 0.81 0.81 0.002 0.01
12 0.76 0.75 0.74 0.0 0.002
15 0.70 0.70 0.69 0.0 0.0
20 0.60 0.60 0.60 0.0 0.0
25 0.50 0.51 0.51 0.0 0.0
---- ---- MAE=0.03 MAE=0.07 Mean FPR=0.09 Mean FPR=0.17
doi:10.1371/journal.pone.0029860.t001
Table 2. CP estimate and FPR on data in normal distribution of size n1=n 2=50 with positive m=2.
k Actual CP Average estimate of CP FPR with C(0.01)=1.628
WCPS NPCPS WCPS NPCPS
1 0.99 0.84 0.62 0.62 0.80
4 0.96 0.92 0.88 0.07 0.27
7 0.93 0.91 0.90 0.01 0.04
9 0.91 0.90 0.89 0.003 0.01
12 0.88 0.87 0.87 0.0 0.0
17 0.83 0.83 0.82 0.0 0.0
22 0.78 0.78 0.78 0.0 0.0
30 0.65 0.70 0.65 0.0 0.0
50 0.50 0.50 0.51 0.0 0.0
---- ---- MAE=0.03 MAE=0.06 Mean FPR=0.08 Mean FPR=0.12
doi:10.1371/journal.pone.0029860.t002
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other two methods in terms of ROC.
The simulation result proved that by adding a weight to the
original function, the proposed method becomes more sensitive to
smaller k.
DGE detection in microarray data of breast-cancer
Result on Dataset I. Dataset I contains microarray data of
49 samples from breast cancer tissues as described in the Material
and Methods section. Based on the previous experiment result,
among the 5293 valid and unique genes of the dataset, NPCPS
(C(0.05)=1.628) yielded a detecting result of 1598 DGE genes and
17 out of 36 top ranked genes were reported as relevant to breast
cancer or other known cancers. By applying the proposed method
to the same dataset, for C(0.05)=1.628, there were 2279 DGE
genes being detected (1258 over expressed genes and 1021 under
expressed genes, respectively); for C(0.05)=1.358, there were 3974
DGE genes being detected (2230 over expressed genes and 1744
under expressed genes, respectively). All the top 50 ranked genes
were reported as cancer-relevant.
Among the recognized differentially expressed genes, most of
them have been reported as involved directly with cancer in
published papers, such as AGER, MAPK14, etc. Some genes
themselves have not yet been reported, but their related genes,
proteins, or behaviors have been reported as cancer-relevant, such
as DGKD (EGFR and DAG related, ranked 481) [20]. Some of
the genes with higher Dn statistic are suspected as participants of
cancer cell lines. For example, gene CCDC130 (ranked 384) is
potentially cancer relevant and currently under research in order
to reveal the characterization of CCDC130 in cancer cell signaling
[21]. Gene ranked in the first 500, such as AHDC1 (ranked 159),
LIG3 (ranked 409), DMD (ranked 75), have not yet been reported
formally as cancer-relevant. However, given the significant
difference between cancer and normal group, it is reasonable to
assume there is high possibility that these genes might participate
in cancer development.
Some of the top 50 genes are listed in Table 6 with the cancer-
relevant description [22–53]. The data distributions of two
typically ranked genes are in Fig. 3 and 4. It is clear that the
estimated change point could locate the actual changing point in
the gene expression data. Particularly, the cancer samples that are
‘more overly expressed’ than the sample on the change point could
be recognized as located in the area specified by the red dashed
lines of CP.
The number of DGE samples of each gene is calculated and the
corresponding histogram of detected DGE genes is displayed in
Fig. 5. For example, there are 1440 non-DGE genes; 376 genes
have DGE in 4 cancer samples; 164 genes have DGE in 12 cancer
samples. Given the cancer group size 24, this histogram
demonstrates that DGE may only exist in cancer subgroup.
Accordingly, the number of differentially expressed genes in
each cancer sample is calculated as shown in Fig. 6. For
example, there are 1057 DGE genes in cancer sample 8, 1380
DGE genes in cancer sample 19, and 1682 DGE genes in cancer
sample 23.
Table 3. CP estimate and FPR on data in normal distribution
of size n1=n 2=25 with different m and k.
m k Actual CP
Average estimate
of CP
FPR
C(0.01)=1.628
24 2 0.96 0.95 0.01
23 4 0.92 0.93 0.01
22 4 0.92 0.91 0.11
22 3 0.94 0.92 0.18
21 9 0.82 0.82 0.32
21 5 0.90 0.85 0.44
3 4 0.92 0.93 0.01
3 5 0.90 0.91 0
4 3 0.94 0.95 0.01
4 5 0.90 0.91 0
doi:10.1371/journal.pone.0029860.t003
Table 4. AUC of ROC curves of the simulation on data in
normal distribution.
Data
Parameter AUC
n m k WCPS NPCPS LRS TriMOST TriORT COPA OS T
50 2 3 0.87 0.79 0.85 0.73 0.81 0.75 0.78 0.72
50 2 5 0.92 0.88 0.92 0.81 0.86 0.86 0.81 0.81
50 2 9 0.98 0.97 0.97 0.92 0.94 0.88 0.81 0.93
100 2 1 0.61 0.50 0.58 0.54 0.58 0.54 0.58 0.53
100 2 4 0.89 0.82 0.83 0.70 0.80 0.72 0.80 0.70
100 2 9 0.97 0.96 0.96 0.84 0.94 0.89 0.90 0.85
50 1 6 0.75 0.72 0.74 0.70 0.64 0.63 0.59 0.70
50 1 9 0.81 0.79 0.80 0.76 0.71 0.67 0.61 0.78
50 1 14 0.89 0.89 0.89 0.88 0.80 0.71 0.61 0.89
100 1 6 0.74 0.70 0.69 0.62 0.62 0.59 0.59 0.64
100 1 9 0.80 0.78 0.75 0.68 0.67 0.63 0.63 0.70
100 1 15 0.89 0.88 0.86 0.81 0.78 0.72 0.67 0.83
Mean AUC 0.84 0.81 0.82 0.75 0.76 0.72 0.70 0.76
doi:10.1371/journal.pone.0029860.t004
Table 5. AUC of ROC curves of the simulation on data in
skew-normal distribution.
Data
Parameter AUC
n mu k WCPS NPCPS LRS TriMOST TriORT COPA OS T
50 2 3 0.81 0.72 0.70 0.66 0.62 0.55 0.56 0.66
50 2 5 0.90 0.86 0.80 0.74 0.70 0.64 0.60 0.76
50 2 9 0.95 0.95 0.90 0.85 0.78 0.64 0.57 0.88
100 2 3 0.80 0.69 0.66 0.59 0.60 0.57 0.57 0.62
100 2 5 0.89 0.84 0.74 0.66 0.66 0.61 0.59 0.69
100 2 9 0.96 0.95 0.86 0.77 0.75 0.67 0.63 0.82
50 1 6 0.68 0.67 0.65 0.65 0.61 0.56 0.55 0.69
50 1 9 0.74 0.75 0.68 0.72 0.63 0.57 0.55 0.75
50 1 14 0.82 0.83 0.71 0.80 0.67 0.59 0.55 0.83
100 1 3 0.61 0.59 0.57 0.55 0.55 0.53 0.54 0.58
100 1 6 0.67 0.65 0.61 0.63 0.59 0.55 0.55 0.64
100 1 20 0.88 0.89 0.73 0.82 0.68 0.61 0.58 0.84
Mean AUC 0.81 0.78 0.72 0.70 0.65 0.59 0.57 0.73
doi:10.1371/journal.pone.0029860.t005
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Material and Methods, Dataset II contains microarray data of
42 samples of 12576 genes, 18 samples of histologically normal
(HN) epithelium from breast cancer patients, 6 samples of high-
risk prophylactic mastectomy (PM) patients, and 18 samples of
reduction mammoplasty patients. After applying WCPS to the
dataset, when threshold is 1.358, there are 9793 over-high
expressed gene and 190 over-low expressed genes, respectively;
when the threshold is 1.628, the over expressed genes reduced to
867 over-high and 10 over-low, respectively. Apparently, this
dataset contains majorly over-high expressed genes. Among the
50 top-ranked genes, 43 genes have been clearly reported as
relevant to human cancer. Among the rest 6 genes, third-ranked
gene AP000944.1 is a lincRNA and long non-coding RNA has
drawn the research attention of its functional role in human
cancer [54]; CENPM gene itself are not yet reported as cancer-
relevant, but inappropriate expression of the centromere proteins
CENP-A and CENP-H could be a major cause of chromosomal
instability that has been recognized as a hallmark of human
cancer [55]; 50-ranked gene HPN cooperates with MYC in the
Figure 1. ROC curves of the simulation on data in normal distribution. (A) n1=n2=25, m=2,k=3. (B) n1=n2=25, m=2 ,k=9 .( C )n1=n2=50,
m=2,k=1.(D)n1=n2=50, m=2, k=4. The x-axis is FPR, and the y-axis is TPR. The significance level a=0.01 for WCPS and NPCPS. Larger area under
ROC curves indicates better sensitivity and specificity. An ROC curve along the diagonal line indicates random-guess.
doi:10.1371/journal.pone.0029860.g001
Figure 2. ROC curves of the simulation on data in skew-normal distribution. (A) n1=n2=25, m=2, k=3. (B) n1=n2=25, m=2 ,k= 5 .( C )
n1=n2=50, m=2,k=3.(D)n1=n2=50, m=2, k=5. The x-axis is FPR, and the y-axis is TPR. The significance level a=0.01 for WCPS and NPCPS. Larger
area under ROC curves indicates better sensitivity and specificity. An ROC curve along the diagonal line indicates random-guess.
doi:10.1371/journal.pone.0029860.g002
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[56].
NPCPS was also applied to this dataset and yielded 2564 and
337 differentially expressed genes with threshold 1.358 and 1.628,
respectively.
WCPS detected much more differentially expressed genes
compared with NPCPS. Moreover, the rankings between these
two methods are only about 50 percent relevant. WCPS
successfully recognized genes that are lower ranked or ignored
by NPCPS. Fig. 7 and Fig. 8 show expression data of several such
genes.
Fig. 9 illustrates the total number of DGE genes in each HN
sample. HN sample 11 and 18, two ER+ breast cancer patient
samples, have more than 6000 differentially expressed genes. HN
sample 1, 2, 9, three ER2 breast cancer patient sample and 13, an
ER+ patient sample have more than 2000 differentially expressed
genes. Fig. 10 is the top ranked gene by WCPS.
The 6 PM samples are from high-risk women and, as in the
work by Graham et al., gene expression in histologically normal
epithelium from breast cancer patients and from cancer-free PM
patients shares a similar profile [57]. Therefore, we also tested the
dataset consisted of 6 PM samples as the case group and 18 RM
Table 6. Cancer-related description of top-ranked genes.
Rank Gene Description
1 AGER Strong expression is seen in cells at the invasive edge of tumors and correlates with invasion and lymph node metastasis
[22]
2 GP1BB Different histological types of lung cancer may be distinguished from normal tissue based on differential DNA methylation
of GP1bbeta [23]
3 PDE4B The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma [24]
4 MAPK14 The expression of p-p38 and uPA was negatively correlated to prognosis of breast cancer [25]
5 SMARCA2 Encodes BRM in the SWI/SNF chromatin-remodeling complex. SWI/SNF related and loss of SWI/SNF-mediated transcriptional
activation increases DNA methylation in cancer cells [26]
6 TCF3 Protein TCF3 no longer binds DNA when modified by a phosphate, making Phosphorylated TCF3 a new diagnostic marker
for cancer [27]
7 NCSTN NCSTN coded protein is a subunit of c-Secretase compound, which is related to Notch signaling, a pathway found
dysregulated in many cancers [28]
8 C9 Upregulation of plasma C9 protein in gastric cancer patients [29]
9 SCARB2 SCARB2 and CSNK1 double negative mRNA expression seems to be predictive of the presence of non-compromised lymph
nodes in oral squamous cell carcinoma [30]
10 BMP1 BMP molecules have further been shown to have an impact on the biological behaviour of breast cancer cells [31]
11 MEF2A Mediates synergistic transcriptional responses to the CaMK and MAPK signaling pathways by signal-dependent dissociation
from histone deacetylases [32], which regulate the expression and activity of numerous proteins involved in both cancer
initiation and cancer progression [33]
12 MYOG Terminal myogenesis switches off cell proliferation and migration, hence, the promotion of rhabdomyosarcoma
differentiation should antagonize tumor growth and metastasis [34]
13 RPL36A Over-expression of RPL36A is associated with cellular proliferation in hepatocellular carcinoma [35]
14 SLC5A5 NIS expression is prevalent in breast cancer brain metastases and could have a therapeutic role via the delivery of
radioactive iodide and selective ablation of tumor cells [36]
15 JAG1 Associated with a basal phenotype and recurrence in lymph node-negative breast cancer [37]
16 MMP11 Expression reflects the stages of tumor differentiation and LNM of breast cancer [38]
17 NEFL Neurofilament proteins are markers for neuroendocrine tumors [38]
18 SLC4A2 (AE2) AE2 might be associated with gastric carcinogenesis and the achlorhydria experienced by gastric cancer patients [40]
27 MYL1 Myosin VI is critical in maintaining the malignant properties of the majority of human prostate cancers diagnosed today [41]
28 IGHD Immunoglobulin D enhances the release of tumor necrosis factor-alpha [42]
29 ZNF131 Repressor of ERalpha signaling [43]
30 RBBP6 Involvement of RbBP6 gene and apoptosis in the pathogenesis of lung cancer [44]
31 IQGAP1 IQGAP1 plays a critical role in colon cancer cell invasion, and therefore diffuse and high expression of IQGAP1 predicts poor
prognosis in patients with colorectal carcinoma [45]
35 UNC119 UNC119 is required for G protein trafficking in sensory neurons [46], while G protein signaling is involved in tumor growth
and angiogenesis [47]
38 PTPRR The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal
tumorigenesis [48]
39 UBB Essential mediator of trichostatin A-induced tumor-selective killing in human cancer cells [49]
40 MGST2 Microsomal glutathione Stransferase II. Glutathione plays a critical role in cellular mechanisms that result in cell death [50]
44 ACAP1 ACAP1 is a GTPase activating protein specific for Arf6 [51], which is required in breast cancer invasive activities [52]
47 NAT6 (FUS2) Function of NAT6 plays an important role in cancer as the gene maps to the chromosomal region 3p21.3, which includes at
least one tumor suppressor gene [53]
doi:10.1371/journal.pone.0029860.t006
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C(0.05)=1.358, there are 7344 over-expressed genes and 79
under-expressed genes, respectively. Fig. 10 shows one of the top-
ranked genes, in which the gene expression of PM samples are not
only over-expressed compared with the RM samples in case
group, but also generally higher than the 18 HN samples from
breast cancer patients.
Fig. 11 summarizes number of DGE genes in each PM
samples. PM sample 1, 2, 4, and 6 have significantly more DGE
genes compared with PM sample 3 and 5. This result corresponds
to the average expression of the total 12576 genes from the 6
samples.
Materials and Methods
Change-point in gene expression
The method we proposed here inherited the definition of
change-point as described in NPCPS [18]. Consider gene
expression value as a sequence of independent variables as below:
X1~x1,:::,xn1,
X2~x1,:::,xn2,
X~X1zX2~x1,:::,xn1,:::,xn,n~n1zn2:
ð1Þ
Here, X1 contains expression values of normal samples in
known distribution function F1 (x), and X2 contains expression
values of cancer samples. Over or under expression values in X2
would result in a change point in X. The existence of change point
is evaluated by a modified Kolmogorov statistic (K-statistic), which
indicates the distance between two distribution functions. Suppose
F1
21 ( y) is the inverse function of F1(x), which is defined as
F{1
1 (y)Dinffx : F1(x)§yg,0vyv1, ð2Þ
where y is a variable increasing with a fixed step that is subject to
user’s selection. Then, the testing procedure is defined as
Figure 4. Data distribution of Gene DECR1, ranked 3487th by WCPS. (A) Empirical distribution functions of cancer and normal group,
respectively, with the expression value at the change-point. (B) Expression data by samples, as well as expression value at the change-point.
doi:10.1371/journal.pone.0029860.g004
Figure 3. Data distribution of Gene AGER, ranked 1st by WCPS. (A) Empirical distribution functions of cancer and normal group, respectively,
with the expression value at the change-point. (B) Expression data by samples, as well as expression value at the change-point.
doi:10.1371/journal.pone.0029860.g003
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1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n{½n   t 
p
X n
i~½nt z1
fI(XiƒF{1
1 (y)){yg,0vtv1,
0vyv1,
ð3Þ
where [n*t] means round toward negative infinity. X has a change
point when sup
0vtv1
sup
0vyv1
Dn(t,y) jj §C(a), where C(a) is the critical
value and a is the significance level, while typical values include
C(0.05)=1.358 and C(0.05)=1.628.
Weighted Change-point Statistic
The aim of NPCPS is to find the largest Dn and check if the
value exceeds the threshold, while the position of the largest Dn
value indicates the most significant changes in the expression
profile of a single gene. According to the ROC curves obtained
from simulation study [18], NPCPS was more than 99% correct
when for a single gene there are more than 9 samples that contain
DGE. However, NPCPS is not very sensitive to the right bound as
shown in Fig. 12. When there is only a small subset of cancer
group, especially when k,5, NPCPS would have inadequate Dn
values and consequently would not always report the existence of
change point. Fig. 13 illustrates the descending trend of Dn value.
When there is no simulated DGE added to the normally
distributed data, Dn function shows a descending curve.
Therefore, in order to enhance the right-bound sensitiveness, it
is reasonable to assume that by adding a proper weight function to
the original function, the Dn statistic could be adequately
compensated even if the change occurs in the last few data points.
Apparently, the goal of the weight function is to moderately
compensate the right end of the Dn statistic to avoid a rigid positive
result, while keeps the Dn value on the left end as well as in the
middle as much as possible, which would resemble a function
similar to 1/x. Besides, as Dn is a step function, the weight function
should also have the same step as Dn statistic.
Figure 5. Histogram: number of DGE genes by size of sample
subsets containing DGE. There are 1440 non-DGE genes; 376 genes
have DGE in 4 cancer samples; 164 genes have DGE in 12 cancer
samples.
doi:10.1371/journal.pone.0029860.g005
Figure 6. Number of significant DGE genes in each cancer
sample of Dataset I. There are 1057 DGE genes in cancer sample 8;
1380 DGE genes in cancer sample 19; 1682 DGE genes in cancer sample
23.
doi:10.1371/journal.pone.0029860.g006
Figure 7. Data distribution and CP of Gene DHCR24 in Dataset
II. (A) Empirical distribution functions of cancer and normal group,
respectively, with the expression value at the change-point. (B)
Expression data by samples, as well as expression value at the
change-point.
doi:10.1371/journal.pone.0029860.g007
Figure 8. Data distribution and CP of Gene PARP12 in Dataset
II. (A) Empirical distribution functions of cancer and normal group,
respectively, with the expression value at the change-point. (B)
Expression data by samples, as well as expression value at the
change-point.
doi:10.1371/journal.pone.0029860.g008
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w~1z1=(n{n   tz1),0vtv1, ð4Þ
and the weighted Dn is defined as
Dn(t,y)D
w
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n{½n   t 
p
X n
i~½nt z1
fI(XiƒF{1
1 (y)){yg,0vtv1,
0vyv1:
ð5Þ
The weighted Dn function demonstrated better response to small
subset that has DGE as shown in Fig. 12. Both estimated change
point and type II error of WCPS show better results compared with
NPCPS. Besides, from Fig. 13 we can see that adding a weight
function does not give an unreasonable rise to the right bound when
there is no DGE in any samples of the simulated data.
Experiment on Breast cancer microarray dataset
Two datasets were tested in the experiment. One microarray
dataset (referred to as dataset I) of breast cancer [58], the same
dataset used in [18] includes 49 samples all from cancer tissues,
with different status of lymph node (LN) and estrogen receptor
(ER), i.e. LN+ER2/LN+ER+/LN2ER+/LN2ER2. As the
negative-lymph-node breast cancer is categorized as early stage
breast cancer, these 49 samples could be categorized into two
types: 25 samples with negative lymph node as the normal samples
and 24 samples with positive lymph node as the cancer samples,
respectively. Besides, gene expression profile of 7129 genes in the
samples was obtained through annotation package hu6800 [59].
Probes of genes obsolete in NCBI gene bank were deleted; for
multiple probes mapping to the same gene, only the probe that
corresponded to the largest Dn was kept. These two steps resulted
in a total 5293 genes. This dataset was tested by all methods
mentioned in simulation study. Before applied to LRS, COPA,
TriMOST, TriORT, OS, and T-statistics, the gene expression
values were first normalized. Before applied to WCPS, the
expression values in cancer group were sorted in ascending order
for each gene.
Figure 9. Number of significant DGE genes in each HN sample
of Dataset II. HN sample 11 and 18, two ER+ breast cancer patient
samples, have more than 6000 differentially expressed genes. HN
sample 1, 2, 9, three ER2 breast cancer patient sample and 13, an ER+
patient sample have more than 2000 differentially expressed genes.
doi:10.1371/journal.pone.0029860.g009
Figure 10. Data distribution and CP of Gene DAPP1 in Dataset
II. Gene expression of PM samples are not only over-expressed
compared with the RM samples in case group, but also generally
higher than the 18 HN samples from breast cancer patients.
doi:10.1371/journal.pone.0029860.g010
Figure 11. Number of significant DGE genes in each PM sample
of Dataset II. PM sample 1, 2, 4, and 6 have significantly more DGE
genes compared with PM sample 3 and 5. This result corresponds to the
average expression of the 12576 genes from the 6 samples.
doi:10.1371/journal.pone.0029860.g011
Figure 12. Estimated change point and type II error of NPCPS.
NPCPS is not very sensitive to the right bound in terms of type II error
and estimated CP position. Both estimated change point and type II
error of WCPS show better results compared with NPCPS.
doi:10.1371/journal.pone.0029860.g012
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obtained on platform Affymetrix Human Genome U133A Array.
The samples contains 3 subsets: 18 samples of normal breast
epithelia from reduction mammoplasty patients (RM sample); 18
samples of histological normal breast epithelia from 9 ER+ and 9
ER2 breast cancer patients (HN samples); and 6 samples of
histologically normal breast epithelium from prophylactic mastec-
tomy patients (PM samples) [57]. 18 RM samples and 6 PM
samples were considered as the control group, while the 18 HN
samples were the case group in the original article. This dataset
was tested by WCPS.
For method NPCPS, LRS, TriMOST, TriORT, COPA, OS
and T-statistic, the genes were ranked according to the different
statistic in descending order. Genes ranked in the top indicated
higher degree of DGE.
For WCPS, change-point was determined by weighted Dn
statistic. Genes with weighted Dn larger than C(a) were recognized
as having DGE. Specially, for detecting result under C(a)=1.358
and based on the type of DGE (over high or over low), sample
values that exceed the expression value at the change-point could
be identified on single gene level. This would result in an array
containing binary values of 0 or 1, where 0 indicates non-DGE
sample and 1 indicates significant DGE sample. Therefore, for all
genes in a dataset, these arrays could be combined to construct a
matrix. Based on the matrix, the DGE genes contained in each
cancer sample, or the size of DGE cancer sample subset could be
calculated.
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